ÌÇÐÄvlog¹ÙÍø Affiliated Authors
Ethel Zimmerman Wiener Professor of Public Policy, ÌÇÐÄvlog¹ÙÍø; Henry and Allison McCance Professor of Business Administration, HBS
Excerpt
Excerpt
November 27, 2024, Paper: "The sole orphan exemption will exclude billions of dollars of Medicare drug spending from price negotiation. The high level of global revenues achieved by these drugs, however, suggests that special exemption is unnecessary for them to achieve financial success. Congress could consider removing the sole orphan exemption to obtain additional savings for patients and taxpayers and to eliminate any potential disincentive for developing additional indications for these drugs."